Cytoreductive nephrectomy

Scott E. Delacroix; Brian F. Chapin; Christopher G. Wood

doi:10.1007/978-3-642-21858-3_7

Cytoreductive nephrectomy

Scott E. Delacroix, Brian F. Chapin, Christopher G. Wood

Urology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Cytoreductive nephrectomy (CN) continues to be an integral part in the contemporary multidisciplinary treatment paradigm for patients with metastatic renal cell carcinoma (mRCC). Unlike many other cancers, removal of the primary tumor in mRCC has been shown to significantly increase overall survival (OS) when combined with postoperative cytokine therapy. Since the FDA approval of the first systemic targeted therapy in 2005, CN has remained prevalent despite controversies regarding the optimal integration of surgery into the contemporary systemic targeted therapy paradigm. Two large phase III randomized trials are underway to assess the role and timing of CN in patients receiving the tyrosine kinase inhibitor, sunitnib malate. While awaiting the results of these trials, it is imperative for the treating physicians to understand the risks associated with CN and optimal patient selection for surgery. This chapter will highlight the historical evolution of CN in the treatment of metastatic RCC, review the data regarding optimal patient selection, discuss the risks of CN, and explore future methods on how to better integrate surgery into the treatment of patients with metastatic RCC.

Original language	English (US)
Title of host publication	Kidney Cancer
Subtitle of host publication	Principles and Practice
Publisher	Springer Berlin Heidelberg
Pages	109-122
Number of pages	14
ISBN (Electronic)	9783642218583
ISBN (Print)	9783642218576
DOIs	https://doi.org/10.1007/978-3-642-21858-3_7
State	Published - Jan 1 2012

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-642-21858-3_7

Cite this

@inbook{7b4456ce7d3a48a1858310787283459f,

title = "Cytoreductive nephrectomy",

abstract = "Cytoreductive nephrectomy (CN) continues to be an integral part in the contemporary multidisciplinary treatment paradigm for patients with metastatic renal cell carcinoma (mRCC). Unlike many other cancers, removal of the primary tumor in mRCC has been shown to significantly increase overall survival (OS) when combined with postoperative cytokine therapy. Since the FDA approval of the first systemic targeted therapy in 2005, CN has remained prevalent despite controversies regarding the optimal integration of surgery into the contemporary systemic targeted therapy paradigm. Two large phase III randomized trials are underway to assess the role and timing of CN in patients receiving the tyrosine kinase inhibitor, sunitnib malate. While awaiting the results of these trials, it is imperative for the treating physicians to understand the risks associated with CN and optimal patient selection for surgery. This chapter will highlight the historical evolution of CN in the treatment of metastatic RCC, review the data regarding optimal patient selection, discuss the risks of CN, and explore future methods on how to better integrate surgery into the treatment of patients with metastatic RCC.",

author = "Delacroix, {Scott E.} and Chapin, {Brian F.} and Wood, {Christopher G.}",

note = "Publisher Copyright: {\textcopyright} Springer-Verlag Berlin Heidelberg 2012.",

year = "2012",

month = jan,

day = "1",

doi = "10.1007/978-3-642-21858-3_7",

language = "English (US)",

isbn = "9783642218576",

pages = "109--122",

booktitle = "Kidney Cancer",

publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Cytoreductive nephrectomy

AU - Delacroix, Scott E.

AU - Chapin, Brian F.

AU - Wood, Christopher G.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Cytoreductive nephrectomy (CN) continues to be an integral part in the contemporary multidisciplinary treatment paradigm for patients with metastatic renal cell carcinoma (mRCC). Unlike many other cancers, removal of the primary tumor in mRCC has been shown to significantly increase overall survival (OS) when combined with postoperative cytokine therapy. Since the FDA approval of the first systemic targeted therapy in 2005, CN has remained prevalent despite controversies regarding the optimal integration of surgery into the contemporary systemic targeted therapy paradigm. Two large phase III randomized trials are underway to assess the role and timing of CN in patients receiving the tyrosine kinase inhibitor, sunitnib malate. While awaiting the results of these trials, it is imperative for the treating physicians to understand the risks associated with CN and optimal patient selection for surgery. This chapter will highlight the historical evolution of CN in the treatment of metastatic RCC, review the data regarding optimal patient selection, discuss the risks of CN, and explore future methods on how to better integrate surgery into the treatment of patients with metastatic RCC.

AB - Cytoreductive nephrectomy (CN) continues to be an integral part in the contemporary multidisciplinary treatment paradigm for patients with metastatic renal cell carcinoma (mRCC). Unlike many other cancers, removal of the primary tumor in mRCC has been shown to significantly increase overall survival (OS) when combined with postoperative cytokine therapy. Since the FDA approval of the first systemic targeted therapy in 2005, CN has remained prevalent despite controversies regarding the optimal integration of surgery into the contemporary systemic targeted therapy paradigm. Two large phase III randomized trials are underway to assess the role and timing of CN in patients receiving the tyrosine kinase inhibitor, sunitnib malate. While awaiting the results of these trials, it is imperative for the treating physicians to understand the risks associated with CN and optimal patient selection for surgery. This chapter will highlight the historical evolution of CN in the treatment of metastatic RCC, review the data regarding optimal patient selection, discuss the risks of CN, and explore future methods on how to better integrate surgery into the treatment of patients with metastatic RCC.

UR - http://www.scopus.com/inward/record.url?scp=84956817444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956817444&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-21858-3_7

DO - 10.1007/978-3-642-21858-3_7

M3 - Chapter

AN - SCOPUS:84956817444

SN - 9783642218576

SP - 109

EP - 122

BT - Kidney Cancer

PB - Springer Berlin Heidelberg

ER -

Cytoreductive nephrectomy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this